How does doxorubicin work? A new mechanism involving cleavage of a transcription factor called CREB3L1 has been proposed to explain the anti-tumour effects of doxorubicin.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of the molecular basis of doxorubicin-induced cardiotoxicity

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1

  2012cited by this paper
• The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells.

  2011cited by this paper
• Regulated intramembrane proteolysis: signaling pathways and biological functions.

  2011cited by this paper
• Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

  2004cited by this paper
• Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

  2001cited by this paper
• Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity

  1999cited by this paper
• A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.

  1999cited by this paper

• Selenium and a newly synthesized Thiocyanoacetamide reduce Doxorubicin gonadotoxicity in male rat.

  2017cites this paper